Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Current Deferred Revenue: 2013-2016

Historic Current Deferred Revenue for Amphastar Pharmaceuticals (AMPH) over the last 3 years, with Sep 2016 value amounting to $830,000.

  • Amphastar Pharmaceuticals' Current Deferred Revenue rose 29.08% to $830,000 in Q3 2016 from the same period last year, while for Sep 2016 it was $830,000, marking a year-over-year increase of 29.08%. This contributed to the annual value of $643,000 for FY2015, which is 95.41% down from last year.
  • Latest data reveals that Amphastar Pharmaceuticals reported Current Deferred Revenue of $830,000 as of Q3 2016, which was down 50.03% from $1.7 million recorded in Q2 2016.
  • In the past 5 years, Amphastar Pharmaceuticals' Current Deferred Revenue ranged from a high of $14.6 million in Q3 2014 and a low of $643,000 during Q4 2013.
  • Over the past 3 years, Amphastar Pharmaceuticals' median Current Deferred Revenue value was $1.2 million (recorded in 2016), while the average stood at $4.5 million.
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Current Deferred Revenue soared by 2,079.32% in 2014, and later plummeted by 95.59% in 2015.
  • Amphastar Pharmaceuticals' Current Deferred Revenue (Quarterly) stood at $643,000 in 2013, then skyrocketed by 2,079.32% to $14.0 million in 2014, then slumped by 95.41% to $643,000 in 2015, then grew by 29.08% to $830,000 in 2016.
  • Its Current Deferred Revenue was $830,000 in Q3 2016, compared to $1.7 million in Q2 2016 and $643,000 in Q1 2016.